Important Information for TransMedics Group, Inc. Securities Investors: Rosen Law Firm Reminds Investors of the Lead Plaintiff Deadline in Securities Class Action
New York, NY – Rosen Law Firm, a global investor rights law firm, reminds purchasers of TransMedics Group, Inc. (NASDAQ: TMDX) securities between February 28, 2023, and January 10, 2025, both dates inclusive (the “Class Period”), of the important April 15, 2025, lead plaintiff deadline in the securities class action first filed by the Firm. This class action seeks to recover damages on behalf of TransMedics investors.
What is the TransMedics Securities Class Action About?
The complaint alleges that TransMedics and certain of its top executives made false and misleading statements and failed to disclose material information during the Class Period, violating the Securities Exchange Act of 1934. Specifically, the complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that:
- TransMedics was experiencing manufacturing issues with its Organ Care System (OCS), which is used to preserve donor organs outside of the body before transplantation;
- The manufacturing issues were causing significant delays in the delivery of OCS units to customers, negatively impacting revenue and earnings;
- The Company was experiencing delays in the regulatory approval process for its OCS in Europe, further impacting revenue and earnings;
- The Company’s financial statements for the fourth quarter of 2023 and full year 2023 were materially false and misleading.
What Does This Mean for TransMedics Investors?
If you purchased TransMedics securities during the Class Period and suffered losses, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline is April 15, 2025. To obtain additional information, you can contact the Rosen Law Firm by calling (212) 686-1061 or emailing [[email protected]](mailto:[email protected]).
What Does This Mean for the World?
The TransMedics securities class action is significant because it highlights the importance of transparency and accuracy in financial reporting. The allegations of manufacturing issues and regulatory delays impacted TransMedics’ revenue and earnings, potentially causing financial harm to investors. The securities class action also serves as a reminder for companies to disclose material information in a timely and accurate manner to investors. Failure to do so can result in legal action and financial consequences.
Conclusion
If you purchased TransMedics securities during the Class Period and suffered losses, you may be entitled to compensation. The lead plaintiff deadline is April 15, 2025. The Rosen Law Firm encourages investors to contact them for more information. This securities class action highlights the importance of transparency and accuracy in financial reporting and serves as a reminder for companies to disclose material information in a timely and accurate manner to investors.
